Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baseline - Preliminary findings from the ADEPT-3 52-week open-label extension provide initial encouraging long-term safety and tolerability data, with symptom score improvements observed